Peer-reviewed veterinary case report
Drugs blocking VEGFR2 and PI3K/Akt/mTOR reduce dog hemangiosarcoma
By Adachi, Mami et al.·Published in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire·2016·Department of Veterinary Clinical Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
- Species:
- dog
Plain-English summary
A study looked at how certain medications could help treat hemangiosarcoma, a serious type of cancer in dogs, particularly affecting the spleen and liver. Researchers tested these medications on cancer cells and found that while some treatments didn't work, others significantly reduced the cancer cell growth and caused the cells to die. This suggests that these specific inhibitors could be a promising option for treating hemangiosarcoma in dogs. More research is needed to see how well these treatments work in real dogs with this condition.
People also search for: dog hemangiosarcoma treatment · canine cancer medication · spleen cancer in dogs · liver cancer in dogs treatment
Abstract
Canine hemangiosarcoma (HSA) is a progressive malignant neoplasm with no current effective treatment. Previous studies showed that receptor tyrosine kinases and molecules within their downstream pathways involving phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (m-TOR) or mitogen-activated protein kinase (MAPK) were overexpressed in canine, human, and murine tumors, including HSA. The present study investigated the effects of inhibitors of these pathways in canine splenic and hepatic HSA cell lines using assays of cell viability and apoptosis. Inhibitors of the MAPK pathway did not affect canine HSA cell viability. However, cell viability was significantly reduced by exposure to inhibitors of vascular endothelial growth factor receptor 2 and the PI3K/Akt/m-TOR pathway; these inhibitors also induced apoptosis in these cell lines. These results suggest that these inhibitors reduce the proliferation of canine HSA cells by inducing apoptosis. Further study of these inhibitors, using xenograft mouse models of canine HSA, are warranted to explore their potential for clinical application.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27408334/